A Phase 3 Study to Evaluate the Efficacy and Safety of 3K3A-APC in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy, or Both in Subjects with Moderate to Severe Acute Ischemic Stroke
Latest Information Update: 05 Oct 2024
At a glance
- Drugs 3K3A APC (Primary)
- Indications Ischaemic stroke
- Focus Registrational; Therapeutic Use
- Acronyms RHAPSODY-2
- Sponsors ZZ Biotech
Most Recent Events
- 30 Sep 2024 Status changed from not yet recruiting to withdrawn prior to enrolment, because NIH funding got suspended.
- 30 Sep 2024 Planned initiation date changed from 1 Dec 2023 to 1 Oct 2024.
- 11 Jul 2023 Planned initiation date changed from 1 Apr 2023 to 1 Dec 2023.